Chewy vs. Uber Technologies: Which Consumer Stock Is a Better Buy in 2026?

Uber is presented as the preferred 2026 growth investment, supported by FY2025 revenue growth of 18.3% to nearly $52.0B and free cash flow of about $9.8B, versus Chewy's 6.2% revenue growth to $12.6B and $562M in FCF. Uber's reported $10.1B net income and 19.3% margin were materially boosted by a one-time tax credit and investment gains, tempering the quality of those earnings. Chewy offers a debt-free balance sheet and expansion into pet healthcare, but faces slower growth, competitive pressure, and regulatory risk; Uber's key risk remains potential driver reclassification and related cost increases.

Analysis

The article’s UBER preference relies too heavily on reported earnings quality; the more investable variable is whether core adjusted EBITDA and FCF continue to scale while incentives remain contained. Uber’s cross-platform network supports lower incremental acquisition cost, but autonomous partnerships are economically ambiguous: successful AV deployment can expand supply and trip volume while shifting value capture toward fleet owners/AV partners rather than the app. Over the next 1-3 months, bookings growth, take-rate stability, and incentive intensity matter more than headline net income; a deceleration in Mobility or Delivery contribution profit would challenge the premium growth narrative quickly.

CHWY’s apparent value is less compelling than its sales multiple suggests because its retail mix remains structurally exposed to AMZN and mass merchants, while health expansion requires upfront clinic, labor, and regulatory investment before margins prove durable. The key upside is that health, pharmacy, insurance, and Autoship can raise customer lifetime value and reduce price comparability; the key downside is that veterinary labor scarcity and licensing restrictions turn a low-capex marketplace-like story into a more capital- and execution-intensive services model. Reported FCF should be haircutted for stock-based compensation when comparing capital-return capacity with UBER.

Consensus likely underestimates the asymmetry in a UBER/LYFT relative trade: regulatory classification risk is sector-wide, but UBER’s diversified delivery and international earnings base provides a partial offset that LYFT lacks. Conversely, if AV commercialization accelerates faster than expected, UBER’s multiple could compress before economics are visible, since investors may reassess its long-run take rate. This is routine comparative commentary rather than a discrete catalyst; avoid chasing either name solely on the article.

Key Decisions for Investors

• Maintain a 3-6 month long UBER / short LYFT pair, sized beta-neutral: UBER should retain superior resilience if U.S. ride-hail pricing softens because delivery and international exposure diversify demand. Reassess if UBER’s quarterly gross-bookings growth falls below low-teens or Mobility adjusted EBITDA margin contracts sequentially while LYFT stabilizes share and pricing.
• Do not initiate directional CHWY from the stated FCF multiple alone. Place an earnings watch: consider a 6-12 month long only if health/pharmacy revenue disclosure shows measurable mix expansion and gross margin improvement without a material rise in fulfillment, clinic, or veterinary-labor costs; otherwise the low P/S ratio is likely a reflection of retail-margin risk rather than mispricing.
• For existing UBER longs, reduce exposure or add downside protection into any regulatory decision that could require broad employee-style benefits in a major U.S. market. A sustained increase in driver incentives or a visible take-rate decline is more thesis-relevant than reported GAAP net income.
• Monitor DASH as the cleaner read-through for delivery promotional intensity. If DASH raises incentives or reports weakening contribution margin, treat that as an early warning for UBER Delivery margin expectations and tighten UBER risk limits.